Related Experiment Video
Updated: Dec 31, 2025
12:42
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
10.0K
Syncytia Formation in Oncolytic Virotherapy
1Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC 29425, USA.
Molecular Therapy Oncolytics
|January 1, 2020
Summary
Syncytia formation enhances oncolytic virus spread in tumors. This review explores naturally occurring and engineered fusogenic viruses for improved cancer virotherapy, addressing challenges in viral dissemination.
Area of Science:
- Oncology
- Virology
- Biotechnology
Background:
- Oncolytic virotherapy utilizes replication-competent viruses for cancer treatment.
- Limited viral spread within the tumor microenvironment is a key challenge.
- Syncytia formation is being investigated to enhance viral dissemination.
Purpose of the Study:
- To review the literature on syncytia formation in oncolytic virotherapy.
- To explore the role of fusogenic viruses in improving cancer treatment.
- To identify future research directions for enhanced viral spread.
Main Methods:
- Literature review of studies on syncytia formation and oncolytic viruses.
- Analysis of naturally occurring and engineered fusogenic viruses.
- Examination of viral spread mechanisms in the tumor microenvironment.
Main Results:
- Naturally fusogenic viruses show oncolytic potential but have limitations.
- Engineered fusogenic viruses enhance non-fusogenic oncolytic viruses.
- Syncytia formation promotes cell-to-cell viral spread.
Conclusions:
- Syncytia formation is a promising strategy to overcome viral spread limitations in oncolytic virotherapy.
- Further research into engineered fusogenic viruses is warranted.
- Optimizing syncytia induction could improve therapeutic outcomes.
Related Concept Videos
02:49Cancer Therapies
9.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K
00:57Viral Recombination
24.8K
Cells are sometimes infected by more than one virus at once. When two viruses disassemble to expose their genomes for replication in the same cell, similar regions of their genomes can pair together and exchange sequences in a process called recombination. Alternatively, viruses with segmented genomes can swap segments in a process called reassortment.
24.8K
01:20Viral Replication: Lytic Cycle
1.1K
Bacteriophages, or phages, are viruses that specifically infect bacteria. Among them, T-even bacteriophages, such as T4, exhibit a well-characterized lytic replication cycle in Escherichia coli (E. coli). This process ensures the rapid proliferation of the virus while ultimately leading to the destruction of the bacterial host.Attachment and DNA InjectionThe infection process begins with the recognition and binding of the T4 phage to the E. coli cell surface. Tail fibers of the phage...
1.1K
01:03Rous Sarcoma Virus (RSV) and Cancer
6.0K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
6.0K
01:30Lytic Cycle of Bacteriophages
77.2K
Bacteriophages, also known as phages, are specialized viruses that infect bacteria. A key characteristic of phages is their distinctive “head-tail” morphology. A phage begins the infection process (i.e., lytic cycle) by attaching to the outside of a bacterial cell. Attachment is accomplished via proteins in the phage tail that bind to specific receptor proteins on the outer surface of the bacterium. The tail injects the phage’s DNA genome into the bacterial cytoplasm. In the...
77.2K
01:51Mechanisms of Retrovirus-induced Cancers
6.7K
Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
6.7K